Therefore, establishment of iPSCs derived from patients with EDSSPD3 (EDSSPD3-iPSCs) will provide opportunities to elucidate the pathogenic mechanisms underlying the loss of ZIP13 functions, and can potentially have clinical and pharmaceutical applications. The gene discussed is SLC39A13; the disease is Ehlers-Danlos syndrome, spondylocheirodysplastic type.